Drug intelligence / Profile preview

docetaxel + sotevtamab

Development stage: Unknown
Lead developer: Alethia Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Docetaxel + sotevtamab is a combination therapy being investigated for the treatment of various cancers, particularly metastatic non-small cell lung cancer (NSCLC) and colorectal cancer. Docetaxel is a taxane derivative that binds to microtubules, promoting assembly and inhibiting disassembly, which leads to cell death by preventing mitotic cell division. Sotevtamab (AB-16B5) is a humanized IgG2 monoclonal antibody that targets secreted clusterin (sCLU), an epithelial-to-mesenchymal transition (EMT)-inducing protein. The combination may enhance immune-mediated anti-tumor response through induction of tumor lysis syndrome (TLS).

Targets

CLU (Clusterin)

Beyond the preview

Go deeper on docetaxel + sotevtamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + sotevtamab.

Explore the full profile